STOCK TITAN

Clearmind Medicine Inc - CMND STOCK NEWS

Welcome to our dedicated news page for Clearmind Medicine (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medicine.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clearmind Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clearmind Medicine's position in the market.

Rhea-AI Summary
Clearmind Medicine Inc. announces an exclusive licensing agreement with Yissum Research Development Company for generation 3.0 psychedelic compounds to treat addiction and mental disorders. The partnership aims to enhance Clearmind's IP portfolio, strengthen its leadership position, and innovate in the field of psychedelic medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
-
Rhea-AI Summary
Clearmind Medicine Inc. (CMND) files a patent application for 3-MMC to treat eating disorders, potentially revolutionizing the weight loss industry. The company aims to address major health issues with novel psychedelic-derived therapeutics, targeting a lucrative market with significant growth potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
-
Rhea-AI Summary
Clearmind Medicine Inc. (Nasdaq:CMND) announces significant progress in developing CMND-100, a groundbreaking MEAI-based formula, for treating alcohol use disorder (AUD) without inducing hallucinations. The Israeli Ministry of Health approved the Phase I/IIa clinical trial for CMND-100, showcasing promising pre-clinical results. Clearmind achieved various milestones in 2023, including FDA meetings, forming a Data and Safety Monitoring Board, securing IRB Approval, and partnering with renowned institutions for clinical trials. The company also unveiled positive outcomes in obesity research, collaborated with pharmaceutical leaders, and expanded its patent portfolio. Looking forward to 2024, Clearmind aims to initiate the Phase I/IIa trial for AUD, enhance strategic alliances, advance obesity research, and introduce an MEAI-based alcohol substitute, promising significant shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.86%
Tags
none
Rhea-AI Summary
Clearmind Medicine Inc. submits its tenth patent application under the PCT in collaboration with SciSparc for a novel composition to prevent and treat depression. The global depression and anxiety disorders treatment market size is projected to reach USD 41.83 billion by 2034.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
-
Rhea-AI Summary
Clearmind Medicine Inc. receives divisional patent approval from China National Intellectual Property Administration for regulating binge behaviors with primary amine aminoindan compounds, enhancing its IP protection in the psychedelic space. The company's innovative molecule, MEAI, shows promise in treating Alcohol Use Disorder and binge drinking.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
Rhea-AI Summary
Clearmind Medicine Inc. receives approval to commence phase I/IIa clinical trial for alcohol use disorder patients using proprietary CMND-100 oral capsule. The trial aims to evaluate safety, pharmacokinetics, and efficacy of the novel psychedelic-derived therapeutic in reducing alcohol consumption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.48%
Tags
Rhea-AI Summary
Clearmind Medicine Inc. has received approval for the voluntary delisting of its common shares from the Canadian Securities Exchange (CSE) while maintaining its listing on the NASDAQ Capital Market under the symbol CMND. The company aims to streamline its trading process, enhance liquidity, and benefit shareholder value by focusing on a single marketplace.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.48%
Tags
none
-
Rhea-AI Summary
Clearmind Medicine Inc. announces the submission of three new patent applications under the international Patent Cooperation Treaty (PCT) in collaboration with SciSparc Ltd. The applications focus on novel compositions of MDMA, Ibogaine, and Ketamine with PEA, enhancing the company's IP protection in the psychedelic space. Clearmind now holds 27 granted patents and 24 pending patent applications across 15 patent families, solidifying its position in the industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Summary
Clearmind Medicine Inc. receives approval to commence phase I/IIa clinical trial for alcohol use disorder patients using proprietary psychedelic MEAI-based CMND-100 oral capsule. The trial aims to evaluate safety, pharmacokinetics, and preliminary efficacy in reducing drinking patterns and cravings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
Rhea-AI Summary
Clearmind Medicine Inc. submits three patent applications under the PCT for novel psychedelic-derived therapeutics in collaboration with SciSparc Ltd., strengthening its IP portfolio. The company now holds 27 granted patents and 24 pending patent applications across 15 patent families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.07%
Tags
none
Clearmind Medicine Inc

Nasdaq:CMND

CMND Rankings

CMND Stock Data

4.04M
3.21M
5.48%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Vancouver